Kameleoon is a serious enterprise experimentation platform, and two details tell you more about it than the feature list does. One is very good. One is a gap.
The good signal
Sample ratio mismatch detection is built in. SRM is when your traffic split does not land where it should, arriving at 52 to 48 rather than 50 to 50. It sounds trivial and it is not, because it almost always indicates a bug in assignment, redirect handling or tracking, and it invalidates the result while the dashboard continues to look normal.
Most teams never check for it. Most platforms do not surface it. A product that detects and flags SRM automatically is telling you that people who actually run experiments designed it, which is a more reliable quality indicator than any amount of AI positioning.
The compliance posture reinforces the same impression. ISO 27001, SOC 2, GDPR, CCPA and HIPAA, with enterprise SSO and MFA. For healthcare, finance and any regulated buyer, that list is frequently the shortlist criterion, and it is unusual to see HIPAA stated this plainly by an experimentation vendor.
The gap
For a testing platform, Kameleoon is notably quiet about its statistics. Nothing published states whether results are frequentist or Bayesian, whether sequential testing is supported, or what threshold declares a winner.
This matters because the method defines what a winner means. A fixed-sample frequentist test, a Bayesian probability-to-beat-control, and a sequential test that permits continuous monitoring will call different results at different moments on identical data. If your team peeks daily at a fixed-sample test, the real false positive rate is far above the number anyone believes.
Predictive Impact Scoring, described as built on data from thousands of experiments, raises the same question in a different form. Effects from other companies’ experiments transfer to yours only under assumptions nobody states. It is a reasonable prior for prioritizing a backlog and a poor substitute for your own result.
None of this suggests the statistics are wrong. It means you cannot assess them before buying, and for the system that will decide what your organization believes about its own website, you should be able to.
The throughput trade
Prompt-Based Experimentation lets teams describe a test conversationally and launch it, and customers report going from a few experiments a quarter to launching in real time.
That is genuine progress if launching was the bottleneck. It is a risk if power was. Cheaper tests mean more tests, and more tests on the same traffic means each one gets less of it. An organization can easily end up running four times as many experiments, reaching significance on none of them, and feeling considerably more data-driven.
Buy this for the compliance coverage, the platform breadth and the SRM discipline. Ask about the statistics on the first call, and pair the throughput gain with a rule about minimum detectable effect before anyone touches the prompt box.
